Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	110.89	108.01	184.43	143.58	221.8
Short-Term Investments	292.74	268.39	183.36	171.91	36.9
Cash & Cash Equivalents	403.63	376.4	367.79	315.49	258.7
Cash Growth	7.23%	2.34%	16.58%	21.95%	238.03%
Receivables	0	1.41	10.26	0.85	0.66
Other Current Assets	15.9	27.49	6.55	6.03	5.88
Total Current Assets	419.52	405.3	384.6	322.37	265.25
Property, Plant & Equipment	335.56	168.59	66.02	47.02	23.21
Long-Term Investments	0	105.87	245.6	137.49	44.18
Goodwill and Intangibles	10.26	11.96	13.66	15.36	17.06
Other Long-Term Assets	0.21	0.22	0.27	0.26	0.14
Total Long-Term Assets	346.03	286.64	325.55	200.13	84.6
Total Assets	765.55	691.94	710.15	522.5	349.85
Accounts Payable	35.87	2.87	9.46	6.83	7.65
Deferred Revenue	0.87	130.05	242.55	19.29	82.8
Current Debt	10.56	2.78	2.25	1.1	0
Other Current Liabilities	58.16	3.16	-107.72	13.47	6.62
Total Current Liabilities	105.46	138.85	146.54	40.68	97.07
Long-Term Debt	104.61	78.8	23.3	20.04	0
Other Long-Term Liabilities	268.33	55.95	131.5	0	8.74
Total Long-Term Liabilities	372.93	134.75	154.79	20.04	8.74
Total Liabilities	478.39	273.6	301.33	60.73	105.81
Total Debt	115.17	81.58	25.55	21.14	0
Debt Growth	41.18%	219.34%	20.85%	-	-
Retained Earnings	-1,026.03	-820.76	-644.69	-503.84	-419.29
Comprehensive Income	-3.22	-0.14	-0.07	0.02	-0.39
Shareholders' Equity	271.34	398.52	408.82	461.78	244.59
Net Cash / Debt	288.46	294.82	342.24	294.36	258.7
Net Cash / Debt Growth	-2.16%	-13.86%	16.27%	13.78%	248.62%
Net Cash Per Share	2.70	2.80	3.30	2.92	2.62
Working Capital	314.07	266.45	238.06	281.69	168.18
Book Value Per Share	2.54	3.78	3.94	4.58	2.61

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).